Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.

Laura L HammittRon DaganYuan YuanManuel Baca CotsMiroslava BoshevaShabir Ahmed Madhi William J MullerHeather J ZarDennis BrooksAmy GrenhamUlrika Wählby HamrénVaishali S MankadPin RenTherese TakasMichael E AbramAmanda LeachM Pamela GriffinTonya Villafananull null

Published in: The New England journal of medicine (2022)

A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection. (Funded by MedImmune/AstraZeneca and Sanofi; MELODY ClinicalTrials.gov number, NCT03979313.).

Keyphrases

respiratory tract
gestational age
preterm infants
low birth weight
preterm birth
respiratory syncytial virus